Your browser doesn't support javascript.
loading
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer.
Malla, Sudhir B; Byrne, Ryan M; Lafarge, Maxime W; Corry, Shania M; Fisher, Natalie C; Tsantoulis, Petros K; Mills, Megan L; Ridgway, Rachel A; Lannagan, Tamsin R M; Najumudeen, Arafath K; Gilroy, Kathryn L; Amirkhah, Raheleh; Maguire, Sarah L; Mulholland, Eoghan J; Belnoue-Davis, Hayley L; Grassi, Elena; Viviani, Marco; Rogan, Emily; Redmond, Keara L; Sakhnevych, Svetlana; McCooey, Aoife J; Bull, Courtney; Hoey, Emily; Sinevici, Nicoleta; Hall, Holly; Ahmaderaghi, Baharak; Domingo, Enric; Blake, Andrew; Richman, Susan D; Isella, Claudio; Miller, Crispin; Bertotti, Andrea; Trusolino, Livio; Loughrey, Maurice B; Kerr, Emma M; Tejpar, Sabine; Maughan, Timothy S; Lawler, Mark; Campbell, Andrew D; Leedham, Simon J; Koelzer, Viktor H; Sansom, Owen J; Dunne, Philip D.
Afiliação
  • Malla SB; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Byrne RM; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Lafarge MW; Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Corry SM; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Fisher NC; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Tsantoulis PK; Faculty of Medicine, Université de Genève, Geneva, Switzerland.
  • Mills ML; Cancer Research UK Scotland Institute, Glasgow, UK.
  • Ridgway RA; Cancer Research UK Scotland Institute, Glasgow, UK.
  • Lannagan TRM; Cancer Research UK Scotland Institute, Glasgow, UK.
  • Najumudeen AK; Cancer Research UK Scotland Institute, Glasgow, UK.
  • Gilroy KL; Cancer Research UK Scotland Institute, Glasgow, UK.
  • Amirkhah R; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Maguire SL; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Mulholland EJ; Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Belnoue-Davis HL; Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Grassi E; Candiolo Cancer Institute, FPO IRCCS, Candiolo, Torino, Italy.
  • Viviani M; Department of Oncology, University of Torino, Candiolo, Torino, Italy.
  • Rogan E; Candiolo Cancer Institute, FPO IRCCS, Candiolo, Torino, Italy.
  • Redmond KL; Department of Oncology, University of Torino, Candiolo, Torino, Italy.
  • Sakhnevych S; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • McCooey AJ; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Bull C; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Hoey E; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Sinevici N; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Hall H; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Ahmaderaghi B; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Domingo E; Cancer Research UK Scotland Institute, Glasgow, UK.
  • Blake A; School of Electronics, Electrical Engineering and Computer Science, Queen's University Belfast, Belfast, UK.
  • Richman SD; Department of Oncology, University of Oxford, Oxford, Oxfordshire, UK.
  • Isella C; Department of Oncology, University of Oxford, Oxford, Oxfordshire, UK.
  • Miller C; Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
  • Bertotti A; Candiolo Cancer Institute, FPO IRCCS, Candiolo, Torino, Italy.
  • Trusolino L; Department of Oncology, University of Torino, Candiolo, Torino, Italy.
  • Loughrey MB; Cancer Research UK Scotland Institute, Glasgow, UK.
  • Kerr EM; School of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Tejpar S; Candiolo Cancer Institute, FPO IRCCS, Candiolo, Torino, Italy.
  • Maughan TS; Candiolo Cancer Institute, FPO IRCCS, Candiolo, Torino, Italy.
  • Lawler M; Department of Oncology, University of Torino, Candiolo, Torino, Italy.
  • Campbell AD; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Leedham SJ; Department of Cellular Pathology, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, UK.
  • Koelzer VH; The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
  • Sansom OJ; Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium.
Nat Genet ; 56(3): 458-472, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38351382
ABSTRACT
Molecular stratification using gene-level transcriptional data has identified subtypes with distinctive genotypic and phenotypic traits, as exemplified by the consensus molecular subtypes (CMS) in colorectal cancer (CRC). Here, rather than gene-level data, we make use of gene ontology and biological activation state information for initial molecular class discovery. In doing so, we defined three pathway-derived subtypes (PDS) in CRC PDS1 tumors, which are canonical/LGR5+ stem-rich, highly proliferative and display good prognosis; PDS2 tumors, which are regenerative/ANXA1+ stem-rich, with elevated stromal and immune tumor microenvironmental lineages; and PDS3 tumors, which represent a previously overlooked slow-cycling subset of tumors within CMS2 with reduced stem populations and increased differentiated lineages, particularly enterocytes and enteroendocrine cells, yet display the worst prognosis in locally advanced disease. These PDS3 phenotypic traits are evident across numerous bulk and single-cell datasets, and demark a series of subtle biological states that are currently under-represented in pre-clinical models and are not identified using existing subtyping classifiers.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article